Featured

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

North America Session – From reaction to result: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

Webinar date:
Supported by Benchling
#Featured Webinars #Webinars

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

Europe Session – From reaction to result: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

Webinar date:
Supported by Benchling
#Featured Webinars #Webinars

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars

#Crown Bioscience #Drug discovery #PDX models #Webinar

Beyond the model: Exploring warm PDX benefits and onsite expertise

Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More

Webinar date:
Supported by Crown Bioscience
#Featured Webinars #Webinars

#Biomarkers #Drug discovery #Evotec #Webinar

From PK/PD and Biomarkers to decision-making: How modeling shapes clinical strategy

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars

Cell and gene therapy
#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy

Advances and challenges in cell and gene therapies

Hosted by Drug Discovery World and supported by Bio-Techne, this webinar explores the advances and challenges taking place within the cell and gene therapy field. Hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo Therapeutics. Throughout the… Read More

Webinar date:
Sponsored by Bio-Techne
#Featured Webinars

Webinars

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery

Next-gen antibody discovery: Leveraging DNA immunisation and single B-cell cloning for high-affinity & specificity rabbit mAbs

Watch this engaging and informative webinar on Fujifilm Wako’s groundbreaking advancements in rabbit monoclonal antibody discovery. Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with its proprietary single B-cell cloning technique, paving the way… Read More

Webinar date:
Supported by Fujifilm Wako
#Webinars

Scientist working in the lab
#3D cell culture #3D modelling #ADME / Tox #Drug toxicity #Pharmokinetics

Building advanced cell models for toxicity testing

Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. Primary cells, media, and reagents are all important for supporting preclinical and clinical pharmaceutical workflows for drug discovery and absorption, distribution, metabolism, excretion, and toxicity (ADMET)… Read More

Webinar date:
Supported by Lonza
#Webinars

#Amino acids #Artificial intelligence (AI) #Biochemistry #Contract Research Organisations (CROs) #Drug discovery

Accelerate drug discovery with AI-AAM: Using AI to discover drugs and improve existing compounds

Traditional drug discovery is time-consuming, and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join FUJIFILM Wako in this webinar to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new proprietary scaffold-hopping method based on AI and chemical… Read More

Webinar date:
Supported by FUJIFILM Wako
#Webinars

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Lab automation #Machine learning

Technology: Artificial intelligence, machine learning and lab automation

In this free webinar, hosted by DDW and sponsored by Benchling, you will learn about technology through the lens of artificial intelligence (AI), machine learning and lab automation. You will hear from Jonathan Wingfield, Principal Scientist at AstraZeneca; Abraham Heifets, CEO at Atomwise; Raminderpal Singh, AI Expert at HitchhikersAI; alongside… Read More

Webinar date:
Sponsored by Benchling
#Webinars

Organoid
#Drug discovery #Human disease models #Organoids #Preclinical development

From patient to petri dish: Replicating disease with patient-derived organoids

Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models. These models often fail to accurately represent the intricate biology of human patients. This webinar explores how patient-derived organoids (HUB Organoids) are revolutionising drug discovery by overcoming these challenges. Read More

Webinar date:
Supported by HUB Organoids
#Webinars

#Biomanufacturing #Biotherapeutics #Drug discovery #GMP #PCR

Innovative strategies for residual DNA and viral titre quantitation using dPCR

Leveraging digital PCR-based assays for the quantitation of residual host cell DNA or viral titres within a biotherapeutic manufacturing workflow offers significant value in ensuring product quality and safety. Digital PCR, or dPCR, is a highly sensitive and precise technique that enables the absolute quantification of nucleic acid targets. In… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#Webinars

Molecular,Model,Of,Antibody
#Drug discovery #Monoclonal antibodies #Therapeutic Antibodies #Webinar

Where is the opportunity in the therapeutic antibody market?

In this webinar, you will hear from Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at Cancer Research Institute; Dr Sheila Keating, VP of Immunology at Gigagen; as well as event sponsors Dr Milind Nigam, Leader – Scientific Solutions Consulting at Benchling, and Dr… Read More

Webinar date:
Brought to you by Benchling & Bio-Rad
#Webinars

#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA

rAAV Genome sequencing uncovers transgene integrity and packaging impurities

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar highlights how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca. You will hear how library preparation, assessed data quality,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#Webinars

Women working in a research laboratory
#Antibody binding #Bioanalytics #Biologics #Biotherapeutics #Characterisation #High Throughput #QA/QC

Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics

Successful development of advanced biotherapeutics relies on extensive characterisation and tight quality control. Characterising binding properties of complex biomolecules is a critical step. Biophysical data combined with functional assays are needed to predict efficacy and potency, optimise drug delivery, assess critical quality attributes, and improve biologics drug design. Traditional approaches have… Read More

Webinar date:
Brought to you by Revvity
#Webinars

#Collaboration #Contract Research Organisations (CROs) #Informatics

Enhancing collaboration between sponsors and contract partners in drug discovery

Most contemporary drug discovery companies (sponsors) outsource some (or all) drug development to external contract partners, eg. Contract Research Organisations (CROs) and/or Contract Development and Manufacturing Organisations (CDMOs). Communication between sponsor and contract organisation is largely done via email and poorly structured Excel reports which is a highly manual, inefficient,… Read More

Webinar date:
Brought to you by Revvity Signals
#Webinars

CRISPR-Cas9
#CRISPR #CRISPR screening #Drug discovery #Genetics / genomics #Single-cell RNA sequencing #Webinar

CRISPR screening at scale: Achieving 1m cell data sets with an instrument-free, cost-effective approach

Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks. Requiring single-cell… Read More

Webinar date:
Brought to you by ScaleBio
#Webinars

A team working in a laboratory
#Biotech #Collaboration #Drug discovery #Lab technology #Torx Software #Webinar

Enhancing collaboration in drug discovery – a biotech perspective

Delivery of synthesis targets within small molecule drug discovery often involves many chemists and other collaborators, both internal and external, across multiple locations. Harnessing skills and knowledge from distributed teams can create challenges for efficiently managing the ideation process and prioritisation, assignment and delivery of agreed targets. Read More

Webinar date:
Brought to you by Cresset
#Webinars

#Biomanufacturing #Biopharmaceuticals #GMP #Microbiology #QA/QC #Webinar

Implementing rapid microbial identification in biotherapy manufacturing

Join DDW for this free on-demand event, Implementing rapid microbial identification in biotherapy manufacturing: Enhancing quality control and regulatory compliance, which is supported by Thermo Fisher Scientific. It is presented by Phil Tuckett, BS, RM(NRCM, Department Scientist, Nelson Laboratories and Michelle Thai, Technical Sales Specialist, Pharma… Read More

Webinar date:
Brought to you by Thermo Fisher Scientific
#Webinars

Cell and gene therapy
#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy #Webinar

Cell & gene therapies: How can market growth be sustained to maximise on opportunities?

In this on-demand webinar, hosted by DDW and sponsored by Astrea Bioseparations, learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). You will hear from Doug Danison, Head of Commercial Strategy and Operations for Bayer CGT, Mark Treherne, Commercial Research Scientist… Read More

Webinar date:
Sponsored by Astrea Bioseparations
#Webinars

#Cancer research #Drug discovery #PROTAC #Protein degradation #Webinar

Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift

As more and more R&D pipelines include PROTAC candidates — the race to bring successful and efficient protein degraders to the clinic is on. These targets present challenges in the biophysical characterisation of binary and ternary complexes, making developing effective degraders complicated. Watch this on-demand webinar to learn: How Spectral… Read More

Webinar date:
Brought to you by NanoTemper
#Webinars

Cancer research
#Cancer research #DDW Turning Science into Business Summit #Drug discovery #Oncology #Taconic #Webinar

DDW Turning Science Into Business Summit: Cancer research opportunities and advances

Join DDW for its Turning Science into Business Summit: Cancer research opportunities and advances. This free online event will be hosted by DDW and is sponsored by Taconic Biosciences. The 2-hour Summit will outline areas of advancement and opportunity in the cancer research market and will consist of presentations from… Read More

Webinar date:
Sponsored by Taconic Biosciences
#Webinars